StockData
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS) stock

KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$11.08−0.31 (-2.72%)

Close on Nov 20, 2026Market cap $219.69MP/E –Yield –

Keros Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Keros Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$48.49M, down 191.3% year over year. For fiscal 2025 it was $105.95M. The highest annual figure on record is $105.95M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$105.95M–
FY2024Dec 31, 2024-$162.80M–
FY2023Dec 31, 2023-$126.97M–
FY2022Dec 31, 2022-$71.30M–
FY2021Dec 31, 2021-$63.17M–
FY2020Dec 31, 2020-$37.19M–
FY2019Dec 31, 2019-$16.27M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$20.58M–
Q1 FY2026Mar 31, 2026-$3.60M-102.2%
Q4 FY2025Dec 31, 2025-$27.43M–
Q3 FY2025Sep 30, 2025$3.12M–
Q2 FY2025Jun 30, 2025-$30.34M–
Q1 FY2025Mar 31, 2025$160.61M–
Q4 FY2024Dec 31, 2024-$46.30M–
Q3 FY2024Sep 30, 2024-$30.89M–
Q2 FY2024Jun 30, 2024-$40.11M–
Q1 FY2024Mar 31, 2024-$45.51M–
Q4 FY2023Dec 31, 2023-$26.00M–
Q3 FY2023Sep 30, 2023-$34.53M–
Q2 FY2023Jun 30, 2023-$31.14M–
Q1 FY2023Mar 31, 2023-$35.30M–
Q4 FY2022Dec 31, 2022-$21.79M–
Q3 FY2022Sep 30, 2022-$24.78M–
Q2 FY2022Jun 30, 2022-$23.16M–
Q1 FY2022Mar 31, 2022-$1.57M–
Q4 FY2021Dec 31, 2021-$19.72M–
Q3 FY2021Sep 30, 2021-$14.59M–
Q2 FY2021Jun 30, 2021-$18.15M–
Q1 FY2021Mar 31, 2021-$10.72M–
Q4 FY2020Dec 31, 2020-$8.05M–
Q3 FY2020Sep 30, 2020-$10.89M–
Q2 FY2020Jun 30, 2020-$9.96M–
Q1 FY2020Mar 31, 2020-$8.30M–
Q4 FY2019Dec 31, 2019-$5.52M–
Q3 FY2019Sep 30, 2019-$3.04M–
Q2 FY2019Jun 30, 2019-$5.20M–
Q1 FY2019Mar 31, 2019-$2.51M–

More Keros Therapeutics figures

See a number that looks wrong?